Clinical Trial Update: An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study [Phase 1, Phase 2]

View source ↗

Summary

Open-label Phase I/II trial evaluating PT-112 in combination with docetaxel in patients with advanced solid tumors and non-small cell lung cancer, including Pha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Solid Tumor

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• PT-112

Snippet

Sponsor: SciClone Pharmaceuticals International (Cayman) Development Limited | Conditions: Advanced Solid Tumor, Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN